Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Cosibelimab |
Trade Name | Unloxcyt |
Synonyms | CK-301|CK 301|TG-1501|TG1501|TG 1501|cosibelimab-ipdl |
Drug Descriptions |
Unloxcyt (cosibelimab) is a human monoclonal antibody against PD-L1 (CD274), which may block immune checkpoint, and lead to anti-tumor immune response (PMID: 37848259). Unloxcyt (cosibelimab) is FDA approved for use in adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation (FDA.gov). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 |
CAS Registry Number | 2216751-26-5 |
NCIT ID | C151947 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Cosibelimab + Pemetrexed Disodium | Carboplatin Cosibelimab Pemetrexed Disodium | 0 | 1 |
Cisplatin + Cosibelimab + Pemetrexed Disodium | Cisplatin Cosibelimab Pemetrexed Disodium | 0 | 1 |
Cosibelimab | Cosibelimab | 0 | 2 |